Market Spotlight: Celiac Disease
Market Spotlight: Celiac Disease
$1,318.00
This Market Spotlight report covers the Celiac Disease market, comprising key pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.
- Description
- Contents
This Market Spotlight report covers the Celiac Disease market, comprising key pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.
Key Takeaways
- Datamonitor Healthcare estimates that in 2016, there were approximately 88.5 million prevalent cases of celiac disease worldwide, and forecasts that number to increase to 97.4 million prevalent cases by 2025.
- Prevalence proportions of celiac disease are highest in Europe and Northern America, and lowest in Africa and Oceania.
- All industry-sponsored drugs in active clinical development for celiac disease are in Phase I or Phase II. Therapies in development for celiac disease focus on targets such as gluten, interleukin 15 receptor, zonulin and zonulin receptor, OX40/CD134 and OX40L, and T-cell receptor. Pipeline drugs for celiac disease are administered orally, as well as via intravenous and intradermal formulations.
- High impact upcoming events for drugs in the celiac disease space comprise topline Phase III trial results for INN-202. There have been six licensing and asset acquisition deals involving celiac disease drugs during 2013–18. The $0.1m agreement between Intrexon and two startups, Genten Therapeutics and CRS Bio, to develop disease-modifying therapies through Intrexon’s proprietary ActoBiotics Lactococcus lactis platform was the only deal with a disclosed value.
- The distribution of clinical trials across Phase I–III indicates that the majority of trials for celiac disease have been in the midphase of development, with 90% of trials in Phase II, and only 10% in Phase I.
- The US has a substantial lead in the number of celiac disease clinical trials globally.
- Innovate Biopharmaceuticals has the highest number of completed trials for celiac disease, with six trials.
- Innovate Biopharmaceuticals leads industry sponsors with the highest number of clinical trials for celiac disease
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Subtypes
9 TREATMENT
10 EPIDEMIOLOGY
14 PIPELINE DRUGS
17 KEY UPCOMING EVENTS
18 LICENSING AND ASSET ACQUISITION DEALS
18 Takeda Funds Celiac Asset As Prelude To Potential Acquisition
19 CLINICAL TRIAL LANDSCAPE
20 Sponsors by status
21 Sponsors by phase
22 BIBLIOGRAPHY
23 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of celiac disease, 2016–25
14 Figure 2: Overview of pipeline drugs for celiac disease in the US
14 Figure 3: Pipeline drugs for celiac disease, by company
15 Figure 4: Pipeline drugs for celiac disease, by drug type
15 Figure 5: Pipeline drugs for celiac disease, by classifications
17 Figure 6: Key upcoming events in celiac disease
18 Figure 7: Licensing and asset acquisition deals in celiac disease, 2013–18
19 Figure 8: Clinical trials in celiac disease
19 Figure 9: Top 10 drugs for clinical trials in celiac disease
20 Figure 10: Top 10 companies for clinical trials in celiac disease
20 Figure 11: Trial locations in celiac disease
21 Figure 12: Celiac disease trials status
21 Figure 13: Celiac disease trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of celiac disease, 2016–25
13 Table 2: Prevalence proportions of celiac disease, by age group, 2016
16 Table 3: Pipeline drugs for celiac disease in the US
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Cymbalta